FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

TECHNOI	BASE TH	(First)	(Middle)	NeuBase 7				rading Sy	mbol		5. Relation	nship of Rep	orting Perso	n(s) to Issue	r
C/O NEUE TECHNOI PITTSBUF	LOGY D	IERAPEU'			2. Issuer Name and Ticker or Trading Symbol NeuBase Therapeutics, Inc. [NBSE]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director X_ 10% Owner				
	DCII DA	(Last) (First) (Middle) C/O NEUBASE THERAPEUTICS, INC., 700 TECHNOLOGY DRIVE, THIRD FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 06/09/2020						X Officer (give title below) Other (specify below) President and CEO			
	(Street) PITTSBURGH, PA 15219				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X_ Form filed by More than One Reporting Person				
					Table I - Non-Derivative Securities Acqui						ired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 8)		(A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)			Ownership of Form:	Beneficial	
					Code	V	Amount	(A) or (D)	Price	(Instr. 3 a	(Instr. 3 and 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common Stock		06/09/2020			P		1,275	A	\$ 7.733	12,525			D (1)		
Common Stock										2,547,639			I	See footnote (2)	
Reminder: Re	eport on a s	eparate line f	or each class of secu	Derivative Se			Per cor the	rsons wh ntained i form dis	no resp n this f splays	form ar a curre	e not requently valid		formation spond unle trol numbe	ss	1474 (9-02)
(Instr. 3) Pr		3. Transactic Date (Month/Day/	on 3A. Deemed Execution D any	(e.g., puts, cal 4.	ls, w	arrants, 5.	optior 6. and (M) vees d d Da	as, conver Date Exer d Expirati (onth/Day)	tible se cisable on Date	curities 7. 7. Ann Un Sec (In: 4)	•		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owners Form of Derivati Security Direct (I or Indire	Beneficia Ownersh (Instr. 4)

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Stephan Dietrich A C/O NEUBASE THERAPEUTICS, INC. 700 TECHNOLOGY DRIVE, THIRD FLOOR PITTSBURGH, PA 15219	X	X	President and CEO				
Lipizzaner LLC C/O NEUBASE THERAPEUTICS, INC. 700 TECHNOLOGY DRIVE, THIRD FLOOR PITTSBURGH, PA 15219		X					

Signatures

/s/ Dietrich Stephan	06/10/2020
**Signature of Reporting Person	Date
/s/ Lipizzaner LLC, by Dietrich Stephan, its sole member	06/10/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares held by Dietrich Stephan as a tenant by the entirety with his spouse.
- (2) Shares held directly by Lipizzaner LLC, of which Dr. Stephan is the sole member.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.